SCHEMBL915932

SCHEMBL915932

COc1cccc(C=NN(OS(=O)(=O)c2ccc(C)cc2)C(=N)N)c1

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PTGS2 P35354 1/20 0.47
LMNA P02545 6/20 0.44
ALDH1A1 P00352 5/20 0.44
HPGD P15428 1/20 0.44
TAAR1 Q96RJ0 1/20 0.44
MAPT P10636 4/20 0.43
NPSR1 Q6W5P4 3/20 0.43
GAA P10253 1/20 0.43
G6PD P11413 1/20 0.43
CHRM5 P08912 1/20 0.41
SMN1; SMN2 Q16637 1/20 0.41
G6PC1 P35575 1/20 0.41
GFER P55789 1/20 0.40
MEN1 O00255 4/20 0.39
KMT2A Q03164 4/20 0.39
NPC1 O15118 2/20 0.39
RAB9A P51151 1/20 0.39
POLB P06746 1/20 0.37
PSMD14 O00487 1/20 0.37
MDM2 Q00987 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7062408 0.86 ALDH1A1 (0.39) PTGS2LMNAALDH1A1HPGDMAPT
SCHEMBL915169 0.84 ALDH1A1 (0.53) PTGS2LMNAALDH1A1HPGDMAPT
SCHEMBL7060004 0.83 GFER (0.42) LMNAALDH1A1HPGDMAPTNPSR1
SCHEMBL7065233 0.82 PTGS2 (0.50) PTGS2LMNAALDH1A1HPGDMAPT
SCHEMBL7066436 0.82 CA2 (0.46) ALDH1A1MAPTGAAMEN1KMT2A
SCHEMBL7064580 0.82 GFER (0.48) PTGS2LMNAALDH1A1HPGDMAPT
SCHEMBL7062299 0.82 GFER (0.48) PTGS2LMNAALDH1A1HPGDMAPT
SCHEMBL915928 0.81 PTGS2 (0.47) PTGS2LMNAALDH1A1HPGDTAAR1
SCHEMBL915930 0.81 PTGS2 (0.47) PTGS2LMNAALDH1A1HPGDTAAR1
SCHEMBL7065388 0.81 ATM (0.38) PTGS2LMNAALDH1A1MAPTGAA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20110015437-A1 USE OF BENZYLIDENEAMINOGUANIDINES AND HYDROXYGUANIDINES AS MELANOCORTIN RECEPTOR LIGANDS ACURE PHARMA AB (SE) 2011-01-20 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110015437-A1 USE OF BENZYLIDENEAMINOGUANIDINES AND HYDROXYGUANIDINES AS MELANOCORTIN RECEPTOR LIGANDS MC1R, MC5R, MCHR1 PTGS2 741/4885LMNA 4609/4885ALDH1A1 1879/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.